Date: 2016-03-16
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016 in New Orleans, LA, USA.
Company: Onxeo (France)
Product: Livatag® (doxorubicin Transdrug®)
Action
mechanism: antineoplastic antibiotic. Livatag® (Doxorubicin Transdrug™) is a doxorubicin formulation in the form of lyophilized nanoparticles of polyisohexylcyanoacrylate (PIHCA).This new therapeutic approach allows drug resistance to be avoided by shortcircuiting the mechanisms of multi-drug resistance developed by tumor cells through the masking of the anticancer agent. Acting as a ‘Trojan horse,’ the nanoparticle formulation avoids rejection of doxorubicin outside the cell so that it can exert its cytotoxic action. By specifically targeting tumor cells in the liver and overcoming resistance to doxorubicin, Livatag® represents a significant breakthrough in the treatment of this cancer.
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology - Rare diseases
Country:
Trial details:
Latest
news: * On March 16, 2016, Onxeo announced that a poster (Abstract 2143 Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma cell lines demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016 in New Orleans, LA, USA. Preclinical studies were conducted in relevant models to evaluate the mechanism of action of doxorubicin loaded nanoparticle formulation (Livatag®) in comparison with free doxorubicin in overcoming hepatocellular carcinoma cellular resistance. The complete data, and their implication on the role of nanoparticles in the treatment of HCC will be discussed at AACR during the poster session by Dr. Graham Dixon, PhD, Chief Scientific Officer at Onxeo. Livatag®’s nanoformulation is designed to accumulate doxorubicin in the liver and evade tumor cell resistance mediated by multiple drug resistance efflux pumps. The efficacy of Livatag® is currently being evaluated in a phase 3 trial (ReLive study) compared to Best Standard of Care (BSC) in patients with advanced hepatocellular carcinomahepatocellular carcinoma.
